

2017 PQMD Forum on Global Aid and Access for Health April 3-6, London, UK





Thank you, and welcome.....

Dear Members, Guests, and Friends of PQMD,

First and foremost, we thank you all for joining us. We look forward to the lively and educational discussions sure to fill the next two days. We sincerely hope that learn something new during your time here with us, and gain an understanding and appreciation for an aspect of global aid and access you had perhaps not been previously exposed to. PQMD is both proud and honored to bring such esteemed names into one place, if only for a brief time, and we anticipate that all in attendance are eager for the days ahead!

Sincerely, Elizabeth "EJ" Ashbourne, Executive Director, PQMD



2017 PQMD Forum General Agenda

Monday, April 3—6pm	No Host Dinner arranged by IHP-UK			
Tuesday, April 4				
8am	Breakfast			
9:15am	PQMD Board Meeting			
11:30am	Mainstreaming Disaster Plenary			
12:30pm	Lunch			
2:30pm	Transition to Reform Club			
3:30pm	Executive Forum @ Reform Club			
5:30pm	Board Dinner @ Reform Club			
Wednesday, April 5				
8am	Breakfast			
9am	Access to Medicines Index Keynote			
9:30am	Access to Medicines Index Plenary			
10:30	Break/Poster Presentations			
10:45	Panel Discussions Group A			
12pm	Lunch			
1pm	Panel Discussions Group B			
2:30pm	Break/Poster Presentations			
3:30pm	Panel Discussions Group C			
5:30pm	Board Reception @ House of Parliament			
Thursday, April 6				
8am	Breakfast			
8:30am	Board Meeting			
11:50am	Lunch			
1pm	Meeting Adjourned			

Reed Smith

London EC2A 2RS

Broadgate Tower, 20 Primrose St,

Tuesday,

April 4

Wednesday,	Reed Smith Broadgate Tower, 20 Primrose St, London EC2A	
April 5	2RS	
7:30am	Breakfast	PQMD Members & Guests
8:30 Welcome		
9am	Access to Medicines Index – Keynote What is the history and impact of the Index? What influence does it have on global health best practices, policies, advocacy, trends and challenges?	Chair – Jeff Sturchio - CEO, Rabin Martin Address: Jayasree Iyer - ATMI, ED
9:30am	Access to Medicines Panel The ATMI index is something that is very important to companies and they are putting large investments into their ratings. This panel will explore why companies find it important. What is the involvement of their partners and NGOs in providing information? Is it making a difference in the way they are investing in CSR and their philanthropic efforts? What are the challenges they are facing and what changes do they make to achieve results?	Chair – Jeff Sturchio -CEO, Rabin Martin Panelists: Jon Pender - GSK Cori Vail - J&J Rebecca Milner - International Medical Corps Harald Nusser - Novartis Jayarsee lyer - ATMI
10:30-10:45	Break	
10:45am	Panel Discussion Group: Access to Medicines – "Access to Medicines and the SDGs" How is access to medicines included in the SDGs? What are the strategies and innovations that are being put in place to ensure that no one is left behind? How can SDGs become central to partnerships? What is needed to mobilize people and resources? How can private philanthropy outside of pharma help with donation impact, particularly around NTDs.	Moderator – Bruce Wilkinson - President and CEO, CMMB Panelists: Francois Bompart - Sanofi Bill Lin – J&J Dan Irvine – World Vision Warren Lancaster – End Fund
10:45am	Panel Discussion Group: Disaster Resiliency — "Pandemic Preparedness" This session will focus on identifying infectious disease and pandemic vectors and donating in complex environments for disasters and pandemics: Providing medical supply donations for disaster response; getting donations to locations of need; getting clarity on needs and requirements to determining how to put medical supply donations into the response. How is impact defined for your donations, and how is the Disaster Medical Supply Network working on the pandemic supply chain initiative with NGOs, industry, and academia. Additionally, this session will address the new efforts WHO is launching to certify NGOs working in disasters, pandemics, and humanitarian assistance.	Moderator — Diana Peters — Lead Coordinator for Health Crisis , GHP Panelists: Amy Kircher - University of MN Sue Mangicaro - HHI Amy Hughes - WHO/University of Manchester Jennifer Olsen - Skoll Foundation

Wednesday, April 5	Continued	
12pm	Lunch	PQMD Members & Guests
1pm	Panel Discussion Group: Disease Elimination— "What Does it Take?" When an organization decides to embark on a prevention, elimination, and eradication effort, what decisions need to be made? What policies, resources, and part- nerships need to be put in place to implement a program? What sort of metrics need to be de- veloped to indicate results and impact? What is the role of external donors and agencies to en- sure success?	Moderator – Mark Chataway - Baird's CMC Panelists: Charlotte Watts - DFID Julie Jenson - Pfizer David Connor – Impact 2030 David Reddy – Medicines for Malaria Ventures Mike Webb - Rotary International Joel Calmet – Sanofi
1pm	Panel Discussion Group: Disaster Resiliency – "Learning from Syria: Health, Crisis, Conflict and Displacement." How are we best able to meet the needs of the long-term displaced? How can security and polit- ical complexities best be balanced against hu- manitarian priorities for neutral alleviation of suffering in this type of conflict? How can corpo- rate medical donation practices be adapted to the collective circumstances faced by refugees and host communities? Based upon the range of experiences thus far within affected communi- ties, response actors, corporations and govern- ment, what can we learn from Syria that will not only enable us to meet current humanitarian obligations but also to ensure that this crisis does not in turn become a fundamentally desta- bilizing crisis for the humanitarian system it- self. Speakers on this panel will address differ- ent aspects of these questions in order to en- gage a broad conversation about the meaning of the Syrian crisis for the present and future of humanitarian assistance and global health phi- lanthropy.	Moderator – Andrew Schroeder - Director of Research and Analysis, DRI Panelists: Irina Mosel - ODI Claire Hitchcock - GSK TBD - Save the Children
2:30-3:30pm	Break	





3:30pm	Panel Discussion Group: Disease Elimination — "How does a company decide to take on an elimination effort." This panel is designed to discuss the issues and challenges that are related to taking on an elimi- nation effort. What decisions need to be made? What policies need to be put in place? What is the role of corporate leadership in making the decision? What sort of resources need to be put in place, including partnerships and other donors? What sort of partners need to be developed to look at a long-term effort? Did it start one way and go another? What are the critical success factors that were decided in the beginning that led to success down the road? How did you learn as you went along?	Moderator – Arnaud Bernaert - Senior Director of Global Health and Healthcare, WEF Panelists: Johannes Waltz - Merck KGA Theresa McCoy - MSD Don Bundy - Gates Melissa Walsh - AbbVie Lucie Graham - COMIC RELIEF
3:30pm	Panel Discussion Group: Access to Medicines – "To Donate or Not to DonateThat is the Question" How do companies decide to donate in a climate of dramatic need and controversy? How do philanthropy, shared value, advocacy policy and CSR come together to support a donation policy? How does a company handle vaccines, devices, and products for chronic diseases, NTDs and other? What are the issues, special skills, and future obligations?	Moderator – Veronica Arroyave - AbbVie Panelists: Jim Mitchum - HHI Ophra Rebiere - Sanofi Jennifer Ferrington – BD Isabela Ribeiro - DNDI
5pm	Meeting Adjourned	
5:30pm	Board Reception House of Commons Dining Room A - Members' Dining Room Cromwell Green Entrance, London SW1A 0AA	PQMD Members & Invited Guests



Executive Forum



Stanley M. Bergman Chairman of the Board and CEO, Henry Schein

Since 1989, Stanley M. Bergman has been Chairman of the Board and CEO of Henry Schein, Inc., a Fortune 500° company and the world's largest provider of health care products and services to office-based dental, animal health, and medical practitioners. Mr. Bergman serves as a board member or advisor for numerous institutions including New York University College of Dentistry; the University of Pennsylvania School of Dental Medicine; the Columbia University Medical Center; Hebrew University; Tel Aviv University; the University of the Witwatersrand Fund; The World Economic Forum's Health Care Governors; the Business Council for International Understanding and the Metropolitan Opera. Mr. Bergman is an honorary member of the American Dental Association and the Alpha Omega Dental Fraternity. His awards include being the recipient of

the Ellis Island Medal of Honor; the CR Magazine Corporate Responsibility Lifetime Achievement Award; an Honorary Doctorate of Commerce from The University of the Witwatersrand, a Doctor of Humane Letters from A.T. Still University's Arizona School of Dentistry and Oral Health, and from Case Western Reserve University; Honorary Fellowship from King's College London - Dental Institute and the International College of Dentists. Stan and Marion Bergman and their family are active supporters of organizations fostering the arts, higher education, cultural diversity and grassroots health care and sustainable entrepreneurial economic development initiatives in the United States, Africa and other developing regions of the world. Mr. Bergman is a graduate of The University of the Witwatersrand in South Africa, and is a South African Chartered Accountant and a NYS Certified Public Accountant (CPA).



Mark Chataway

Co-Chairman, Baird's CMC
Mark Chataway is an expert in
policy analysis and development, opinion research and
communications. Mark is the
Director of Hyderus Cyf, a
consultancy based in Wales
and co-chairman of Baird's
CMC, a global consultancy

group owned by 40 shareholders in over 30 countries. He has worked for governments such as the European Commission, India and South Africa; for intergovernmental organisations such as the International AIDS Vaccine Initiative, the IBSA alliance, Gavi and the WHO; for non-governmental groups such as the Bill & Melinda Gates Foundation and PATH and for all of the world's major vaccine research and production companies.



Bonnie Jenkins

Visiting Fellow, Univ. of PA
Bonnie Jenkins currently
serves as a University of Pennsylvania Perry World House —
Brookings Institute Visiting
Fellow. From 2009 — January
2017, Jenkins served as Ambassador, U.S. Department of
State, as Coordinator for

Threat Reduction Programs in the Bureau of International Security and Nonproliferation. . Jenkins has a Ph.D. in international relations from the University of Virginia; an LL.M. in international and comparative law from the Georgetown University Law Center; an M.P.A. from the State University of New York at Albany; a J.D. from Albany Law School; and a B.A. from Amherst College.



Sr. Dir. Global Health, WEF
Prior to joining the World
Economic Forum as Senior
Director of Global Health and

Arnaud Bernaert

Director of Global Health and Healthcare, Arnaud was Senior Vice President at Royal Philips in charge of Global Strategy, Business Development, and M&A for Philips

Healthcare, the \$13B in sales unit of Royal Philips based in Boston. Formally the SVP and CFO for Philips Home Healthcare Solutions, Arnaud joined Philips in 2005 from Baxter Healthcare, where he acted as the European Regional Controller for Baxter \$2.5 B business. A finance MBA from HEC Paris by education, Arnaud has accumulated more than 20 years of experience in the Healthcare industry.



Jeffrey Sturchio

President & CEO
Rabin Martin
Jeffrey L. Sturchio is President
and CEO at Rabin Martin, a
global health strategy consulting firm, and former President and CEO of the Global
Health Council. Before joining
the Council in 2009, Dr. Stur-

chio was vice president of Corporate Responsibility at Merck & Co. Inc., president of The Merck Company Foundation and chairman of the U. S. Corporate Council on Africa (CCA). He received an AB in history from Princeton University and a PhD in the history and sociology of science from the University of Pennsylvania.



Douglas Jackson

President & CEO, Project C.U.R.E.

Dr. Douglas Jackson serves as the President/CEO of Project C.U.R.E. Since 1987, Project C.U.R.E. has delivered equipment and supplies to hospitals and clinics in over 130 countries. Douglas graduated

magna cum laude from Northwest Nazarene University in 1982, receiving a Bachelor of Arts in Business Administration. In 1985, he earned a Juris Doctor from the University of Colorado at Boulder, receiving the American Jurisprudence Award for Excellence in the study of law. In 1992, he was awarded a Ph.D. in Business Administration with an emphasis in finance and econometrics from the University of Colorado at Boulder



Martha Newsome

President & CEO, Medical
Teams International
Martha Holley Newsome joined
Medical Teams International in
September 2016 as President and
CEO. Martha holds a Master's
degree in Public Health from the
Johns Hopkins School of Hygiene

and Public Health. Martha has spent the last 30 years addressing international health needs including leading World Vision International's Global Sustainable Health team which includes their global programs in food, health and nutrition, and water, sanitation, and hygiene and represents global teams of over 3000 employees and a budget of \$700M. She has lived and worked in Mozambique as a national director and in South Africa where she oversaw World Vision's HIV&AIDS work in 26 African countries.

Moderators & Keynote Speakers



Stefano Scuratti Senior Consultant, The Economist Intelligence Unit-UNISDR Stefano is the lead representative

of The EIU's Public Policy, Economics and Politics Consulting practice in South-East Asia. He has led a variety of engagements on

issues such as international trade, peace and security, disaster risk, obesity, and public-private partnerships in the infrastructure sector, frameworks.



Veronica Arroyave

Director, Corporate Responsibility & AbbVie Foundation Verónica Arroyave is the Director of Corporate Responsibility and AbbVie Foundation for AbbVie. In that capacity, she advances

AbbVie's commitment as a socially responsible company supporting global philanthropic programs and alliance building. She has advised for organizations such as Johnson & Johnson, Schering-Plough, Wyeth, Project HOPE, Medical Teams International and Carilion Foundation. Veronica has a Bachelors of Science from Our Lady of Holy Cross College, a Masters from Tulane University's School Public Health & Tropical Medicine and a Ph.D. from Virginia Tech's School of Public and International Affairs.



Andrew Schroeder

Director of Research & Analysis, Direct Relief Andrew is a world recognized leader in the use of geographic information systems (GIS) for humanitarian aid and global health, having designed interac-

tive mapping projects for partners ranging from the CDC, UNDP, UNFPA and Rockefeller Foundation to Pfizer, Abbvie and BD. He received his PhD in Social and Cultural Analysis from New York University and his \$30 million in less than 10 years. She has also Masters in Public Policy from the Ford School at the University of Michigan.



Bruce Wilkinson

President & CEO, CMMB In the field of global poverty alleviation, CMMB chief executive officer Bruce Wilkinson brings deep experiential understanding and a belief that sustainable solutions develop only

when people are empowered to solve their own challenges. During 25 years at World Vision, he was instrumental in mobilizing U.S. commitments to invest in the US President's Emergency Plan for AIDS Relief (PEPFAR), one of the world's largestever international health initiatives. He has a bachelor of arts degree in economics from Gordon College and an MBA in international management from Cambridge University, England, with additional diploma studies in linguistics, French, and anthropology.



Javasree Iver

Executive Director, Access to Medicine Founda-Jayasree K. Iyer leads the strategic direction, research programmes and stakeholder outreach of the Access to Medicine Foundation. She is responsible for the Access to Medicine

Index, the upcoming Access to Vaccines Index and the various thematic studies into priority health topics published by the Foundation.



Erica Tavares

Sr. Dir., Institutional Advancement, International Medical Corps

Erica Tavares leads partnership development and private fundraising efforts at International Medical Corps. Erica was previ-

ously a member of the management team at Women for Women International, helping to grow their annual revenue from \$1 million to more than worked with the Democratic National Committee and received her BA from American University.

Guests & Speakers



Jon Pender Vice President, Government Affairs, Global Health—GSK



Cori Vail
Project Leader—J&J GCI



Rebecca Milner
VP, Institutional
Advancement—
International
Medical Corps



Harald Nusser Head— Novartis Social Business



Francois
Bompart
VP, Access to
Medicines—
Sanofi



Bill Lin Director, NTDs—J&J GCI



Dan Irvine
Sr. Dir. of Operations,
Health & Nutrition—World
Vision Intl.



Warren Lancaster SVP of Programs— The END Fund



Amy Kircher
Director, Food
Protection &
Defense Institute—Univ. of
Minnesota



Susan Mangicaro Exec. Director Global Response—Heart to Heart Intl.



Amy Hughes Lecturer in Emergency Humanitarian Response—Univ.



Jennifer
Olsen
Manager, Pandemics—Skoll
Global Threats
Fund



Diana Peters Coordinator, Health Crises— German Health Partners



Charlotte
Watts
Chief Scientific
Adviser/Dir., Research and Evidence Division—
DFID

Guests & Speakers, contd.



David Connor
Regional Voice
Lead—Impact
2030



Julie Jenson
Director—
Pfizer



David Reddy
CEO—Medicines
for Malaria
Venture



Irina Mosel Sr. Research Fellow—ODI



Mike Webb International Director— Rotary



Joel Calmet Sr. Director, Scientific Communications— Sanofi Pasteur



Claire Hitchcock Director—GSK



Olimpia de la Rosa Humanitarian Health Advisor—Save the Children



Johannes Waltz MD—Merck KGA



Theresa McCoy Associate Director, Corporate Responsibility —MSD



Don Bundy Sr. Advisor, NTDs—The Bill & Melinda Gates Foundation



Jim
Mitchum
CEO—Heart to
Heart
International



Melissa Walsh VP, AbbVie Foundation— AbbVie



Lucie Graham
International
Grants Programme Manager for Health—
Comic Relief



Ophra
Rebiere VP,
CSR—Sanofi



Jennifer
Farrington
Sr. Director, BD
and VP of BD
Foundation



Isabela
Ribeiro
Scientific Lead,
DNDi Dynamic
Portfolio Unit—
DNDi



Elizabeth
Ashbourne
Executive
Director—PQMD



Amy Dupuis

VP—Sanofi Foundation for North

America & Chair of
the Board—PQMD

Our Sponsors

Thank you to all of the members who generously donated time and expertise in bringing this forum together. We could not have done this without you! In particular, we wish to thank AbbVie, BD, Henry Schein, GSK, Pfizer, and Sanofi.













Thank you for attending!

2017 PQMD Forum on Global Aid and Access for Health April 3-6, London, UK



